C. Diff clinical trials at UCSD
3 in progress, 1 open to eligible people
To Compare Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection
open to eligible people ages 18 years and up
Summit is developing ridinilazole as a novel antimicrobial for Clostridium difficile Infection (CDI) with the goal of achieving comparable cure rates to standard of care, but reducing rates of recurrent disease. A phase 2 proof of concept study, with vancomycin as comparator, demonstrated these attributes with a comparable safety profile. A high fecal concentration of ridinilazole and little systemic exposure were noted. The rationale for this phase 3 study is to confirm the improvement in sustained clinical response of CDI over vancomycin and to compare the safety and tolerability of ridinilazole to that of vancomycin.
La Jolla, California and other locations
Clostridium Difficile Vaccine Efficacy Trial
Sorry, in progress, not accepting new patients
The Clover trial is evaluating an investigational vaccine that may help to prevent Clostridium difficile infection. Participants in the study are adults 50 years of age and older, who are at risk of developing Clostridium difficile infection. The study will assess whether the vaccine prevents the disease, and whether it is safe and well tolerated. Each subject will receive 3 doses of Clostridium difficile vaccine or placebo and be followed for up to 3 years after vaccination for potential Clostridium difficile infection.
San Diego, California and other locations
Optimal Treatment for Recurrent Clostridium Difficile
Sorry, in progress, not accepting new patients
The purpose of this study is to determine whether fidaxomicin and vancomycin followed by taper and pulse vancomycin treatment are superior to standard vancomycin treatment for the treatment of recurrent Clostridium difficile infection.
San Diego, California and other locations
Last updated: